| 1 |
34624079 |
10.1182/blood.2021012081 |
2022 |
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. |
BCR |
| 2 |
34795418 |
10.1038/s41375-021-01470-4 |
2022 |
Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models. |
BCR |
| 3 |
34882582 |
10.1172/JCI153283 |
2022 |
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. |
BCR |
| 4 |
34952433 |
10.1016/j.ejmech.2021.114051 |
2022 |
Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK). |
BCR |
| 5 |
35051110 |
10.3390/vetsci9010026 |
2022 |
Feline and Canine Cutaneous Lymphocytosis: Reactive Process or Indolent Neoplastic Disease? |
BCR |
| 6 |
35077445 |
10.1371/journal.pone.0261469 |
2022 |
T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival. |
BCR |
| 7 |
35082399 |
10.1038/s41417-021-00415-4 |
2022 |
CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma. |
BCR |
| 8 |
35126963 |
10.1177/20406207211072839 |
2022 |
MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. |
BCR |
| 9 |
35158410 |
10.1111/ejh.13755 |
2022 |
Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. |
BCR |
| 10 |
35181934 |
10.1111/vcp.13062 |
2022 |
A challenging case of lymphoproliferative disease in a cat. |
BCR |
| 11 |
35205606 |
10.3390/cancers14040860 |
2022 |
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas. |
BCR |
| 12 |
35205731 |
10.3390/cancers14040983 |
2022 |
Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart. |
BCR |
| 13 |
35218741 |
10.1016/j.bcp.2022.114977 |
2022 |
Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases. |
BCR |
| 14 |
35230873 |
10.1126/scisignal.abk3083 |
2022 |
Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells. |
BCR |
| 15 |
35255496 |
10.1182/bloodadvances.2021006147 |
2022 |
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. |
BCR |
| 16 |
35257981 |
10.1016/j.drup.2022.100822 |
2022 |
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. |
BCR |
| 17 |
35266562 |
10.1002/ajh.26523 |
2022 |
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. |
BCR |
| 18 |
35295854 |
10.3389/fcell.2022.838871 |
2022 |
Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells. |
BCR |
| 19 |
35296646 |
10.1038/s41419-022-04684-1 |
2022 |
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. |
BCR |
| 20 |
35306137 |
10.1016/j.cellsig.2022.110311 |
2022 |
B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells. |
BCR |
| 21 |
35350909 |
10.1177/10781552221090869 |
2022 |
Real-world management of targeted therapies in chronic lymphocytic leukemia. |
BCR |
| 22 |
35398488 |
10.1016/j.cellsig.2022.110331 |
2022 |
SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. |
BCR |
| 23 |
35411950 |
10.1002/cbf.3702 |
2022 |
USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma. |
BCR |
| 24 |
35416325 |
10.1002/hon.3004 |
2022 |
LncRNA FIRRE stimulates PTBP1-induced Smurf2 decay, stabilizes B-cell receptor, and promotes the development of diffuse large B-cell lymphoma. |
BCR |
| 25 |
35435617 |
10.1007/s11864-022-00953-5 |
2022 |
Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T. |
BCR |
| 26 |
35440579 |
10.1038/s41467-022-29835-y |
2022 |
A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. |
BCR |
| 27 |
35450208 |
10.1177/20406207221090886 |
2022 |
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. |
BCR |
| 28 |
35472072 |
10.1371/journal.ppat.1010453 |
2022 |
Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells. |
BCR |
| 29 |
35478711 |
10.2147/CMAR.S353022 |
2022 |
Primary Testicular and Cutaneous Philadelphia Chromosome Positive B-Cell Lymphoblastic Lymphoma: A Rare Case and Review. |
BCR |
| 30 |
35482146 |
10.1007/s11307-022-01733-1 |
2022 |
[<sup>18</sup>F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase. |
BCR |
| 31 |
35484682 |
10.3324/haematol.2021.280557 |
2022 |
Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. |
BCR |
| 32 |
35548364 |
10.3389/fphar.2022.834113 |
2022 |
Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. |
BCR |
| 33 |
35574218 |
10.18632/oncotarget.28228 |
2022 |
Proteomic analysis reveals dual requirement for Grb2 and PLCγ1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation. |
BCR |
| 34 |
35577905 |
10.1038/s41375-022-01596-z |
2022 |
Changing causes of death in persons with haematological cancers 1975-2016. |
BCR |
| 35 |
35588855 |
10.1016/j.ab.2022.114736 |
2022 |
Various types of electrochemical biosensors for leukemia detection and therapeutic approaches. |
BCR |
| 36 |
35597428 |
10.1016/j.cellsig.2022.110358 |
2022 |
BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. |
BCR |
| 37 |
35597806 |
10.1038/s41375-022-01598-x |
2022 |
Inability to phosphorylate Y88 of p27<sup>Kip1</sup> enforces reduced p27 protein levels and accelerates leukemia progression. |
BCR |
| 38 |
35611214 |
10.2147/IJN.S355408 |
2022 |
Transcriptomics-Based Investigation of Molecular Mechanisms Underlying Apoptosis Induced by ZnO Nanoparticles in Human Diffuse Large B-Cell Lymphoma. |
BCR |
| 39 |
35745866 |
10.3390/pharmaceutics14061294 |
2022 |
Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia. |
BCR |
| 40 |
35774848 |
10.1155/2022/3276925 |
2022 |
Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. |
BCR |
| 41 |
35785180 |
10.3389/fonc.2022.901797 |
2022 |
Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series. |
BCR |
| 42 |
35802654 |
10.1371/journal.pone.0270710 |
2022 |
Development and application of a next-generation sequencing protocol and bioinformatics pipeline for the comprehensive analysis of the canine immunoglobulin repertoire. |
BCR |
| 43 |
35804999 |
10.3390/cancers14133229 |
2022 |
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma. |
BCR |
| 44 |
35885931 |
10.3390/genes13071144 |
2022 |
Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group. |
BCR |
| 45 |
35916333 |
10.1002/dc.25027 |
2022 |
HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review. |
BCR |
| 46 |
35920412 |
10.1002/jbt.23185 |
2022 |
Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. |
BCR |
| 47 |
35941532 |
10.1186/s10020-022-00518-0 |
2022 |
Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma. |
BCR |
| 48 |
35953718 |
10.1038/s41591-022-01927-8 |
2022 |
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. |
BCR |
| 49 |
35983732 |
10.1080/10428194.2022.2098291 |
2022 |
Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. |
BCR |
| 50 |
36029036 |
10.1111/bjh.18418 |
2022 |
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. |
BCR |
| 51 |
36035991 |
10.3389/fcell.2022.935023 |
2022 |
Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma. |
BCR |
| 52 |
36051037 |
10.1002/jha2.475 |
2022 |
B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens. |
BCR |
| 53 |
36068158 |
10.1016/j.clml.2022.07.017 |
2022 |
Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review. |
BCR |
| 54 |
32193251 |
10.3324/haematol.2019.242701 |
2021 |
The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma. |
BCR |
| 55 |
32273478 |
10.3324/haematol.2020.251579 |
2021 |
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. |
BCR |
| 56 |
32675228 |
10.3324/haematol.2019.241653 |
2021 |
Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. |
BCR |
| 57 |
32785655 |
10.1182/blood.2019004713 |
2021 |
Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. |
BCR |
| 58 |
32910713 |
10.1080/15548627.2020.1821546 |
2021 |
TFG is required for autophagy flux and to prevent endoplasmic reticulum stress in CH12 B lymphoma cells. |
BCR |
| 59 |
33024996 |
10.1182/blood.2020004996 |
2021 |
Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice. |
BCR |
| 60 |
33094664 |
10.1080/15476286.2020.1838783 |
2021 |
LncRNAs in adaptive immunity: role in physiological and pathological conditions. |
BCR |
| 61 |
33125593 |
10.1007/s00411-020-00879-2 |
2021 |
Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries. |
BCR |
| 62 |
33225446 |
10.1002/path.5592 |
2021 |
Classification of intestinal T-cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status. |
BCR |
| 63 |
33272709 |
10.1016/j.bioorg.2020.104385 |
2021 |
Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML. |
BCR |
| 64 |
33303420 |
10.1016/j.clml.2020.10.009 |
2021 |
Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study. |
BCR |
| 65 |
33303632 |
10.1074/jbc.RA120.015285 |
2021 |
A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. |
BCR |
| 66 |
33373915 |
10.1016/j.biopha.2020.111166 |
2021 |
Yishen-tongbi decoction inhibits excessive activation of B cells by activating the FcγRIIb/Lyn/SHP-1 pathway and attenuates the inflammatory response in CIA rats. |
BCR |
| 67 |
33419778 |
10.1158/1078-0432.CCR-20-3741 |
2021 |
Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. |
BCR |
| 68 |
33427570 |
10.1080/10428194.2020.1864352 |
2021 |
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. |
BCR |
| 69 |
33432783 |
10.1111/ijlh.13456 |
2021 |
Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment. |
BCR |
| 70 |
33513604 |
10.1182/blood.2020008835 |
2021 |
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. |
BCR |
| 71 |
33554816 |
10.19746/j.cnki.issn.1009-2137.2021.01.028 |
2021 |
[Characteristic of 8p11 Myeloproliferative Syndrome with Rare Phenotype]. |
BCR |
| 72 |
33570628 |
10.1182/bloodadvances.2020001665 |
2021 |
Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. |
BCR |
| 73 |
33591648 |
10.1002/brb3.2061 |
2021 |
New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL). |
BCR |
| 74 |
33639170 |
10.1016/j.jbc.2021.100465 |
2021 |
TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells. |
BCR |
| 75 |
33672947 |
10.3390/biology10020152 |
2021 |
HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases. |
BCR |
| 76 |
33728464 |
10.1182/blood.2020009855 |
2021 |
Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. |
BCR |
| 77 |
33752626 |
10.1186/s12885-021-08015-z |
2021 |
Establishment of a typing model for diffuse large B-cell lymphoma based on B-cell receptor repertoire sequencing. |
BCR |
| 78 |
33768841 |
10.1002/ccr3.3770 |
2021 |
High-grade B-cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib. |
BCR |
| 79 |
33814500 |
10.2169/internalmedicine.7066-21 |
2021 |
BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy. |
BCR |
| 80 |
33851691 |
10.1358/dot.2021.57.4.3264113 |
2021 |
Tirabrutinib hydrochloride for B-cell lymphomas. |
BCR |
| 81 |
33853871 |
10.1128/mSphere.00093-21 |
2021 |
B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition. |
BCR |
| 82 |
33896586 |
10.1016/j.bulcan.2021.01.014 |
2021 |
[Richter Syndrome: Diagnostic and Therapeutic Management]. |
BCR |
| 83 |
33912159 |
10.3389/fimmu.2021.627602 |
2021 |
The <i>Traf2</i>DNx<i>BCL2-tg</i> Mouse Model of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recapitulates the Biased IGHV Gene Usage, Stereotypy, and Antigen-Specific HCDR3 Selection of Its Human Counterpart. |
BCR |
| 84 |
33921415 |
10.3390/cancers13081837 |
2021 |
Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells. |
BCR |
| 85 |
33990705 |
10.1038/s41379-021-00817-7 |
2021 |
Myeloid/lymphoid neoplasms with FLT3 rearrangement. |
BCR |
| 86 |
33999145 |
10.1182/bloodadvances.2020003566 |
2021 |
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. |
BCR |
| 87 |
34000704 |
10.1016/j.bioorg.2021.104968 |
2021 |
Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma. |
BCR |
| 88 |
34049715 |
10.1016/j.pathol.2021.02.013 |
2021 |
Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis. |
BCR |
| 89 |
34115047 |
10.1097/MD.0000000000026323 |
2021 |
Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review. |
BCR |
| 90 |
34120550 |
10.1080/14656566.2021.1941864 |
2021 |
Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma. |
BCR |
| 91 |
34158358 |
10.1158/1078-0432.CCR-20-5039 |
2021 |
SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma. |
BCR |
| 92 |
34158825 |
10.3332/ecancer.2021.1221 |
2021 |
T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association. |
BCR |
| 93 |
34160140 |
10.1002/adbi.202100220 |
2021 |
Functional Phenotype Flow Cytometry: On Chip Sorting of Individual Cells According to Responses to Stimuli. |
BCR |
| 94 |
34177947 |
10.3389/fimmu.2021.689472 |
2021 |
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. |
BCR |
| 95 |
34190698 |
10.22034/iji.2021.84496.1661 |
2021 |
Distinguishing Isolated Lymphoid Extramedullary Blast Crisis and Secondary Non-Hodgkin Lymphoma in Chronic Myelogenous Leukemia: a Case Report and Review of the Literature. |
BCR |
| 96 |
34195068 |
10.3389/fonc.2021.608238 |
2021 |
Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma. |
BCR |
| 97 |
34248965 |
10.3389/fimmu.2021.681984 |
2021 |
A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. |
BCR |
| 98 |
34263144 |
10.1097/HS9.0000000000000620 |
2021 |
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells. |
BCR |
| 99 |
34264564 |
10.20892/j.issn.2095-3941.2020.0291 |
2021 |
SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation. |
BCR |
| 100 |
34314938 |
10.1016/j.bmc.2021.116275 |
2021 |
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors. |
BCR |
Datasets
Models
